168 related articles for article (PubMed ID: 23712318)
1. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Galsky MD; Xie W; Nakabayashi M; Ross RW; Fennessy FM; Tempany CM; Choueiri TK; Khine K; Kantoff PW; Taplin ME; Oh WK
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):266-70. PubMed ID: 23712318
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
4. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
9. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
[TBL] [Abstract][Full Text] [Related]
11. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Bergstrom CP; Ruffell B; Ho CM; Higano CS; Ellis WJ; Garzotto M; Beer TM; Graff JN
Anticancer Drugs; 2017 Jan; 28(1):120-126. PubMed ID: 27669423
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
[TBL] [Abstract][Full Text] [Related]
15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
16. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
[TBL] [Abstract][Full Text] [Related]
19. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
